AKESO INC. O.N. (4RY) - Total Assets
Based on the latest financial reports, AKESO INC. O.N. (4RY) holds total assets worth €16.00 Billion EUR (≈ $18.71 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AKESO INC. O.N. shareholders equity for net asset value and shareholders' equity analysis.
AKESO INC. O.N. - Total Assets Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s total assets have evolved over time, based on quarterly financial data. Check 4RY financial resilience to evaluate the company's liquid asset resilience ratio.
AKESO INC. O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
AKESO INC. O.N.'s total assets of €16.00 Billion consist of 70.5% current assets and 29.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 54.9% |
| Accounts Receivable | €1.02 Billion | 6.4% |
| Inventory | €931.62 Million | 5.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €321.50 Million | 2.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4RY stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AKESO INC. O.N.'s current assets represent 70.5% of total assets in 2025, an increase from 65.6% in 2021.
- Cash Position: Cash and equivalents constituted 54.9% of total assets in 2025, down from 55.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
AKESO INC. O.N. Competitors by Total Assets
Key competitors of AKESO INC. O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
AKESO INC. O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.14 | 5.15 | 4.79 |
| Quick Ratio | 4.71 | 4.73 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.08 Billion | €7.00 Billion | €5.34 Billion |
AKESO INC. O.N. - Advanced Valuation Insights
This section examines the relationship between AKESO INC. O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.77 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | 25.4% |
| Total Assets | €16.00 Billion |
| Market Capitalization | $13.02 Billion USD |
Valuation Analysis
Near Book Valuation: The market values AKESO INC. O.N.'s assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: AKESO INC. O.N.'s assets grew by 25.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AKESO INC. O.N. (2021–2025)
The table below shows the annual total assets of AKESO INC. O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €16.00 Billion ≈ $18.71 Billion |
+25.44% |
| 2024-12-31 | €12.75 Billion ≈ $14.91 Billion |
+38.93% |
| 2023-12-31 | €9.18 Billion ≈ $10.73 Billion |
+67.05% |
| 2022-12-31 | €5.50 Billion ≈ $6.43 Billion |
+14.36% |
| 2021-12-31 | €4.81 Billion ≈ $5.62 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more